Heart Benefits of GLP-1 Medications Fade Shortly After Stopping Therapy

Patients may lose critical heart protection within months of stopping glucagon-like peptide–1 (GLP-1) medications, according to CNN.¹ GLP-1 receptor agonists, including semaglutide and tirzepatide, are widely prescribed for type 2 diabetes and obesity management, offering benefits that extend beyond blood sugar control. Among the most compelling advantages is a notable reduction in cardiovascular risk, including heart attacks, strokes, and other heart-related complications.

A recent study published in BMJ Medicine underscores that these heart-protective effects are largely lost when patients discontinue therapy. Researchers examined medical records from over 333,000 patients with type 2 diabetes treated through the Veterans Health Administration. Of these, approximately 132,000 patients were prescribed GLP‑1 receptor agonists, while more than 201,000 were prescribed sulfonylureas, an older class of diabetes medications.

Patients who remained on GLP‑1 therapy for an average of 3 years experienced significant cardiovascular benefits, with an 18% lower risk of heart attacks, strokes, or death compared with those on sulfonylureas. However, those who stopped taking the medication began losing these protective effects within months. Six months after discontinuation, cardiovascular risk had increased by 4% compared to continuous users. At 1 year, the risk had risen 14%, and by the second year, it had climbed 22%, effectively erasing nearly all the benefit accrued during treatment.

This aligns closely with results from the SELECT (NCT03574597) trial, which reported that semaglutide reduced the risk of major cardiovascular events by roughly 20% in people with obesity, independent of weight loss.² The trial suggests that GLP‑1 therapy confers both weight-dependent and weight-independent cardiovascular benefits, potentially through direct effects on heart tissue and systemic inflammation.

The findings carry critical implications for clinical practice. While GLP‑1 medications are often initiated for weight management, their cardiovascular benefits appear to require sustained therapy.¹ Many patients discontinue these drugs within the first year, often due to gastrointestinal side effects, fatigue, or high cost. Therefore, insurers and health systems should consider the evolving evidence, noting that discontinuation may expose patients to unnecessary cardiovascular risk.

The study also highlights a distinction between the benefits of short-term vs long-term therapy. Those who maintain continuous GLP‑1 use achieve the greatest cardiovascular protection, while patients who stop the medication lose these gains relatively quickly. GLP‑1 medications may provide both weight-dependent and weight-independent benefits to the heart, suggesting a direct effect on cardiovascular tissue in addition to improvements related to weight loss.

Although questions remain—such as whether maintaining weight loss after stopping therapy preserves any cardiovascular benefit—the message suggests that for patients at risk of heart disease, GLP‑1 receptor agonists should be considered a chronic therapy rather than a short-term intervention.

Clinicians should counsel patients on the importance of sustained treatment for cardiovascular protection and proactively address barriers to long-term adherence, including side effect management and affordability. Policy makers and payers may also need to reassess coverage strategies to align with the growing evidence that stopping therapy prematurely can reverse heart benefits.

Although GLP‑1 receptor agonists offer substantial protection against heart attacks, strokes, and cardiovascular death, these benefits are rapidly lost when the medication is discontinued. Sustained use is key to maintaining long-term heart health for patients with type 2 diabetes.

References

1. Goodman B. Heart benefits fade after stopping GLP-1 medications. CNN. March 18, 2026. Accessed March 18, 2026. https://www.cnn.com/2026/03/18/health/glp-1-medications-heart-benefits-study

2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563